dr. camidge on the profile 1007 trial: crizotinib vs pemetrexed or docetaxel in nsclc
Published 10 years ago • 234 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:37
dr. camidge on the alex trial in patients with alk nsclc
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc
-
2:29
dr. ross camidge discusses crizotinib in ros1 rearranged nsclc
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
1:55
dr. d. ross camidge on targeted therapies in adjuvant non-small cell lung cancer
-
1:58
dr. shaw on crizotinib in alk-positive lung cancer
-
3:21
phase 1 study of crizotinib in patients with alk-positive non-small cell lung cancer
-
0:44
dr. mark kris discusses crizotinib for patients with alk-positive lung cancer
-
1:40
dr. langer discusses the jmen maintenance pemetrexed trial
-
1:35
dr. camidge on low testosterone in patients with alk-positive lung cancer
-
1:35
d. ross camidge discusses the development of a new lung cancer drug
-
2:05
updates from the profile 1001 study
-
1:28
dr. camidge on ap26113 in patients with advanced malignancies
-
1:00
dr. camidge discusses unmet needs in alk lung cancer
-
1:29
dr. camidge on the unmet needs for lung cancer
-
0:56
crizotinib for first line treatment of alk or ros1 rearrangements
-
1:47
alk rearrangements: what are they, and who has them?
-
12:46
gracecast-086_lung-cancer_q&a with drs. solomon and camidge on alk inhibition for advanced nsclc
-
1:01
what is an alk-positive cancer?